Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

This study found that baricitinib, taken for 24 weeks, significantly reduced alopecia severity in patients with moderate-to-severe alopecia areata, with 50% showing marked improvement and overall favorable safety and efficacy reported.

This study found that topical clobetasol propionate cream provided a modest improvement in hair regrowth for alopecia areata patients, though those with atopy had higher relapse rates after treatment completion.

This study analyzed data from 2083 patients with alopecia areata in Europe and found that those with atopic, autoimmune, or psychiatric comorbidities encountered more severe disease and were more likely to require advanced treatments compared to those without comorbid conditions.

In this study, withdrawal of baricitinib therapy in patients with severe alopecia areata who had achieved hair regrowth led to a loss of benefit in almost all patients, suggesting that continued treatment is necessary to maintain hair regrowth.

This review discusses the evaluation, diagnosis, and management of beard alopecia areata and reports no new clinical results, though it highlights recent treatment advances with janus kinase inhibitors.

This study found that most dermatologists in the Middle East manage mild to severe alopecia areata primarily with potent topical corticosteroids and identified long-term disease control and improved efficacy as key unmet needs.

This study evaluated the agreement between clinician and patient assessments of eyebrow and eyelash hair loss severity in adults with severe alopecia areata, using data from two phase 3 studies over 52 weeks.

This source notes that Olumiant (baricitinib), a rheumatoid arthritis drug by Eli Lilly and Company, has been approved as the first systemic treatment for severe alopecia areata.

This narrative review reflects on the challenges faced by FDA's Oncologic Drugs Advisory Committee members, highlighting public pressure, decision-making complexity, and the evolving landscape of cancer drug development.

This study found that among placebo-treated patients in the BRAVE-AA trials, the likelihood of spontaneous hair regrowth in untreated severe alopecia areata was low, with only a small percentage achieving significant scalp, eyebrow, or eyelash hair improvement over 36 weeks.

This study found that anthralin and mechlorethamine were the most effective therapies among those tested in AA-affected rodent models, providing a basis for further analysis of their mechanisms in Alopecia Areata.

This study found that twice-daily oral baricitinib at a 2-mg dose showed promising results in treating refractory alopecia areata, particularly among Chinese patients, with 64% achieving significant hair regrowth, although none attained complete hair regrowth. Adverse events were mild and included nausea and folliculitis.

This retrospective study at the University Clinical Centre in Gdańsk reported that 77.9% of patients with alopecia areata were treated with off-label pharmacotherapy, predominantly glucocorticosteroids, highlighting a reliance on these therapies in European clinical practice.

This study conducted a survey among consultant dermatologists in Ireland to explore their use of JAK inhibitors for treating alopecia areata, acknowledging challenges posed by the lack of global guidelines and long-term safety data.

This review discusses the composition, activation, and regulation of the JAK/STAT pathway and highlights its role and inhibitors in various diseases, but reports no new experimental results.

This review discusses the shift in toxicity profiles of cancer therapies from traditional chemotherapy to targeted agents, noting similar overall toxicities but with different side effects, and reports no new findings.

This review discusses case reports of autoimmune diseases following vaccination and the challenges of establishing a clear epidemiological connection, urging further investigation into vaccine-induced autoimmunity.

This review discusses the role of lncRNA Xist in cell growth regulation and disease development, particularly cancer, and reports no new experimental results.

This review discusses the disproportionate negative impact of the COVID-19 pandemic on individuals with chronic medical conditions and calls for strategies to protect these vulnerable populations.

This meta-analysis estimated that around 80% of patients who had COVID-19 experienced at least one long-term symptom, with fatigue being the most common reported effect.

This review suggests that allogenic adipose stem cell and extracellular matrix transplants may be safe and effective for various medical conditions, based on available studies.

This review discusses how overlapping risk factors in women with polycystic ovary syndrome may heighten their risk for severe COVID-19, advocating for integrated care approaches but provides no new clinical results.

This review discusses the potential of various Indian herbal medicines in treating cognitive impairment related to Alzheimer's disease but reports no new clinical findings; it highlights the need for further research.

This scoping review found that while some small human pilot trials of extracellular vesicles as therapeutics showed promising outcomes, variability in study design and lack of placebo controls limit definitive conclusions about their safety and efficacy.

This study suggests that enhancing glycolysis in MSCs may improve their immune functions and therapeutic potential, although more evidence is needed to understand the direct metabolic mechanisms involved.

This review discusses the therapeutic potential of mesenchymal stem cell-derived extracellular vesicles and modern technologies like 3D bioprinting but reports no new clinical results.

This review highlights ongoing efforts in drug repurposing and development of new therapeutics against COVID-19, emphasizing the promise of these strategies in addressing the challenges posed by SARS-CoV-2 mutations and post-infection complications.

Effective vaccines and treatments are crucial for long-term COVID-19 control.

This review summarizes the therapeutic potential and development of engineered extracellular vesicles for tissue repair and regenerative medicine, reporting no new clinical findings.